Holen Sie sich die Stockscreener-App
11.09
0.81%
-0.035
Schlusskurs vom Vortag:
$11.05
Offen:
$10.61
24-Stunden-Volumen:
360.60K
Relative Volume:
0.12
Marktkapitalisierung:
$11.42M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-1.13M
KGV:
-0.1939
EPS:
-57.1626
Netto-Cashflow:
$-2.63M
1W Leistung:
+49.52%
1M Leistung:
+110.42%
6M Leistung:
+118.14%
1J Leistung:
-99.28%
1-Tages-Spanne:
$10.20
$11.73
1-Wochen-Bereich:
$6.07
$18.20
52-Wochen-Spanne:
$2.88
$7,200.00
Polyrizon Ltd Stock (PLRZ) Company Profile
Vergleichen Sie PLRZ mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLRZ
Polyrizon Ltd
|
10.96 | 11.51M | 0 | -1.13M | -2.63M | -57.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.92 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.61 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.54 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
892.07 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.97 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Polyrizon Ltd Aktie (PLRZ) Neueste Nachrichten
Polyrizon Ltd. (PLRZ) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Polyrizon completes FDA pre-submission meeting for allergy blocker - Investing.com
Polyrizon Advances PL-14 Nasal Spray with FDA Meeting - TipRanks
Polyrizon completes FDA pre-submission meeting for allergy blocker By Investing.com - Investing.com India
Polyrizon completes FDA pre-submission meeting for PL-14 nasal spray - TipRanks
Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray - The Manila Times
Polyrizon completes FDA pre-submission meeting for PL-14 allergy blocker nasal spray - marketscreener.com
Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray - GlobeNewswire Inc.
Top Biotech Stocks To ConsiderDecember 4th - MarketBeat
Small Cap Stocks To Keep An Eye OnDecember 4th - MarketBeat
Biotech Alert: Searches spiking for these stocks today - TipRanks
This Former Penny Stock Just Doubled for the Second Time This Week. Should You Chase the Rally Here? - Barchart.com
Morning Market Movers: SMX, PRAX, PLRZ, RBRK See Big Swings - RTTNews
Polyrizon Ltd. Announces $4.97 Million Securities Offering - TipRanks
We Think Polyrizon (NASDAQ:PLRZ) Can Afford To Drive Business Growth - Yahoo Finance
Top Medical Stocks To Keep An Eye On – December 2nd - Defense World
Polyrizon (PLRZ) Stock Explodes on Naloxone Hydrogel Breakthrough and PL‑14 Upscaling – What Investors Should Know Now - ts2.tech
Polyrizon Surges: A Game-Changer in Progress? - StocksToTrade
Polyrizon (PLRZ) Stock Doubles on Naloxone Hydrogel Breakthrough and PL‑14 Manufacturing Milestone – What Investors Need to Know on December 4, 2025 - ts2.tech
Why Is Polyrizon Stock Skyrocketing Thursday?Polyrizon (NASDAQ:PLRZ) - Benzinga
Polyrizon (NASDAQ: PLRZ) Soars as Superior Mucoadhesion Naloxone Hydrogel Signals Stronger Real-World Opioid Overdose Reversal Potential - Barchart.com
Polyrizon Stock Skyrockets: What Sparked This Surge? - timothysykes.com
Morning Market Movers: PLRZ, PMI, CBIO, HY See Big Swings - RTTNews
Polyrizon (Nasdaq: PLRZ) scales PL-14 nasal spray output for planned 2026 clinical trials - Stock Titan
PLRZ Stock Price and Chart — NASDAQ:PLRZ - TradingView
Why Did Polyrizon Stock Soar Pre-Market Today? - Stocktwits
What Sparked Polyrizon's (PLRZ) 140% After-Hours Stock Surge? - Benzinga
Polyrizon Announces Superior Results for Intranasal Naloxone Hydrogel - TipRanks
PLRZ’s Strategic Moves Spark Investor Curiosity Amid Stock Fluctuations - timothysykes.com
Polyrizon reports positive mucoadhesion results for intranasal naloxone hydrogel - marketscreener.com
Polyrizon Ltd (PLRZ) Stock Soars on Nasal Spray Milestone: Latest News, AI Forecasts and Risk Outlook – December 3, 2025 - ts2.tech
Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product - The Manila Times
Polyrizon’s nasal naloxone gel shows stronger mucoadhesion in study - Investing.com
Polyrizon’s nasal naloxone gel shows stronger mucoadhesion in study By Investing.com - Investing.com Australia
Polyrizon (Nasdaq: PLRZ) reports naloxone hydrogel mucoadhesion gains vs approved spray - Stock Titan
Polyrizon Achieves Scaled Manufacturing Milestone for PL-14 Intranasal Allergy Spray - Contract Pharma
S&P 500, NASDAQ and Dow Jones end in green as Wall Street bounces back with Bitcoin boost, Polyrizon rises - The Economic Times
Polyrizon (PLRZ) Stock Soars Over 130% on Nasal Spray Breakthrough: Is This Micro-Cap Biotech the Next Big Winner or a Speculative Trap? - ts2.tech
Polyrizon Ltd. (PLRZ) Stock: Soars as Breakthrough Manufacturing Milestone Ignites Momentum - parameter.io
Polyrizon Ltd.: Rapid Stock Movement – What’s Next? - StocksToTrade
Polyrizon (PLRZ) Stock: Nasal Spray Breakthrough Triggers Massive 108% Rally - parameter.io
Polyrizon completes manufacturing upscaling for nasal spray technology By Investing.com - Investing.com India
Polyrizon completes manufacturing upscaling for nasal spray technology - Investing.com
PLRZ’s Dramatic Leap: An Eye-Opening Analysis - timothysykes.com
Polyrizon completes manufacturing upscaling milestone for nasal spray platform - TipRanks
Polyrizon Achieves Key Manufacturing Milestone for Nasal Spray Platform - TipRanks
Polyrizon stock soars after successful manufacturing upscaling milestone By Investing.com - Investing.com UK
Polyrizon stock soars after successful manufacturing upscaling milestone - Investing.com
Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its ... - Bakersfield.com
Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform - marketscreener.com
Polyrizon (Nasdaq: PLRZ) scales up PL-14 nasal spray production for 2026 trial - Stock Titan
Finanzdaten der Polyrizon Ltd-Aktie (PLRZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):